Pint Pharma Secures ANVISA Approval for BESREMi® in PV Treatment
Pint Pharma Secures ANVISA Approval for BESREMi® in PV Treatment Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment…
Poxel Reports Positive Preclinical Results for PXL065 in HCM
Poxel Reports Positive Preclinical Results for PXL065 in HCM POXEL SA, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for chronic and serious diseases with metabolic pathophysiology, including metabolic…
Verastem Oncology Q4 & Full-Year 2024 Results, Business Updates
Verastem Oncology Q4 & Full-Year 2024 Results, Business Updates Verastem Oncology, a biopharmaceutical company dedicated to developing innovative therapies for cancer patients, has announced its financial results for the fourth…
GRM Information Management to Exhibit at USCAP Annual Meeting
GRM Information Management to Exhibit at USCAP Annual Meeting GRM Information Management (GRM) is set to showcase its specialized pathology storage services at the prestigious United States and Canadian Academy…
NeuroSense Moves Closer to Early Canadian ALS Drug Launch
NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug NeuroSense Therapeutics Ltd. has announced significant progress toward the early commercialization of PrimeC in Canada. According to a Form 6-K…
Cardurion Pharma Names Karen Lewis Chief People Officer
Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer, Strengthening Leadership Amid Growth Cardurion Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on discovering and developing new therapeutic approaches for cardiovascular…
Kairos Pharma Publishes Breakthrough on Overcoming Drug Resistance in NSCLC
Kairos Pharma Publishes Breakthrough on Overcoming Drug Resistance in NSCLC Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, has announced a significant breakthrough in addressing drug resistance to EGFR-targeted therapies for…
InnoCare Doses First Patient in Phase III Trial of ICP-488 for Psoriasis in China
InnoCare Doses First Patient in Phase III Trial of ICP-488 for Psoriasis in China InnoCare Pharma, a leading biopharmaceutical company dedicated to developing innovative treatments for cancer and autoimmune diseases,…
BPGbio to Present Novel E2-Based TPD Program at 5th Annual Summit
BPGbio to Present Novel E2-Based TPD Program at 5th Annual Summit BPGbio, Inc., a leading biology-first, AI-powered, clinical-stage biopharmaceutical company focused on mitochondrial biology and protein homeostasis, has announced its…
Optum Rx Revamps Pharmacy Payments
Optum Rx to Modernize Pharmacy Payment Models Rising drug prices set by pharmaceutical manufacturers are placing significant financial strain on pharmacies across the United States. As the cost of prescription…
MiNA Therapeutics Adds Norbert Bischofberger to Board, Bríd Ryan as CSO
MiNA Therapeutics Adds Norbert Bischofberger to Board, Bríd Ryan as CSO MiNA Therapeutics Limited, a leader in the development of small activating RNA (RNAa) therapeutics, has announced key leadership changes…
Triastek’s 3D-Printed T20G Gets FDA IND Clearance
Triastek announced that on February 27, 2025, its proprietary 3D-printed non-vitamin K antagonist oral anticoagulant (NOAC) product, T20G, received Investigational New Drug (IND) clearance from the U.S. Food and Drug…